Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Castration Levels of Testosterone; Hormone-Resistant Prostate Cancer; Microsatellite Instability Interventions: Biological: Durvalumab; Other: Laboratory Biomarker Analysis Sponsors: University of Washington; National Cancer Institute (NCI) Not yet recruiting - verified November 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hormone Resistant Prostate Cancer | Hormones | Prostate Cancer